References
1. Clift AK, et al. Living risk prediction algorithm (QCOVID) for risk
of hospital admission and mortality from coronavirus 19 in adults:
national derivation and validation cohort study. BMJ. 2020;371:m3731.
2. Vaduganathan M, et al. Renin–Angiotensin–Aldosterone System
Inhibitors in Patients with Covid-19. New England Journal of Medicine.
2020;382(17):1653-9.
3. Akhtar S, et al. Pharmacotherapy in COVID-19 patients: a review of
ACE2-raising drugs and their clinical safety. Journal of Drug Targeting.
2020;28(7-8):683-99.
4. Baral R, et al. Effect of renin-angiotensin-aldosterone system
inhibitors in patients with COVID-19: a systematic review and
meta-analysis of 28,872 patients. Current atherosclerosis reports.
2020;22(10):1-9.
5. Pirola CJ, et al. Estimation of Renin-Angiotensin-Aldosterone-System
(RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. J Infect.
2020;81(2):276-81.
6. Zhang X, et al. ACEI/ARB use and risk of infection or severity or
mortality of COVID-19: a systematic review and meta-analysis. Pharmacol
Res. 2020;158:104927.
7. Aromataris E, et al. Summarizing systematic reviews: methodological
development, conduct and reporting of an umbrella review approach. JBI
Evidence Implementation. 2015;13(3).
8. Aromataris E, et al. JBI Manual for Evidence Synthesis. In:
Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis2020.
9. Covidence. Better systematic review management 2022 [Available
from: https://www.covidence.org/home.
10. House AE, et al. Measures of interobserver agreement: Calculation
formulas and distribution effects. Journal of behavioral assessment.
1981;3(1):37-57.
11. Shea BJ, et al. AMSTAR 2: a critical appraisal tool for systematic
reviews that include randomised or non-randomised studies of healthcare
interventions, or both. Bmj. 2017;358:j4008.
12. Higgins JP, et al. Measuring inconsistency in meta-analyses. Br Med
J. 2003;327(7414):557-60.
13. Egger M, et al. Bias in meta-analysis detected by a simple,
graphical test. BMJ. 1997;315(7109):629-34.
14. Higgins JP, et al. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1. 0 [updated March 2011]. The Cochrane
Collaboration: The Cochrane Collaboration; 2011 [Available from:
https://handbook-5-1.cochrane.org/.
15. Mander A, et al. Assessing the influence of a single study in
meta-analysis. Stata Tech Bull Reprints. 1999;8:108-10.
16. Abdulhak AAB, et al. Angiotensin Converting Enzyme Inhibitors and
Angiotensin Receptor Blockers and Outcome of COVID-19 : A Systematic
Review and Meta-analysis. medRxiv. 2020:2020.05.06.20093260.
17. Alamer A, et al. Mortality in COVID-19 patients treated with
ACEIs/ARBs: re-estimated meta-analysis results following the Mehra et
al. retraction. Pharmacol Res. 2020;160:105053.
18. Asiimwe IG, et al. Cardiovascular drugs and COVID‐19 clinical
outcomes: a living systematic review and meta‐analysis. Br J Clin
Pharmacol. 2021.
19. Barochiner J, et al. Use of inhibitors of the renin‐angiotensin
system in hypertensive patients and COVID‐19 severity: A systematic
review and meta‐analysis. J Clin Pharm Ther. 2020;45(6):1244-52.
20. Barochiner J, et al. Use of inhibitors of the renin angiotensin
system and COVID-19 prognosis: a systematic review and meta-analysis.
medRxiv. 2020:2020.05.19.20106799.
21. Beressa TB, et al. Effect of Renin-Angiotensin-Aldosterone System
inhibitors on outcomes of COVID-19 patients with hypertension:
Systematic review and Meta-analysis. medRxiv. 2020:2020.09.03.20187393.
22. Bezabih YM, et al. Comparison of renin–angiotensin–aldosterone
system inhibitors with other antihypertensives in association with
coronavirus disease-19 clinical outcomes: systematic review and
meta-analysis. medRxiv. 2020:2020.05.21.20108993.
23. Cai XJ, et al. Impact of angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers on in-hospital mortality in COVID-19
patients: a systematic review and meta-analysis. Singapore Med J.
2020;1:16.
24. Caldeira D, et al. Angiotensin-converting enzyme inhibitors and
angiotensin-receptor blockers and the risk of COVID-19 infection or
severe disease: systematic review and meta-analysis. IJC Heart &
Vasculature. 2020;31:100627.
25. Chan C-K, et al. Renin-angiotensin-aldosterone system inhibitors and
risks of severe acute respiratory syndrome coronavirus 2 infection: a
systematic review and meta-analysis. Hypertension. 2020;76(5):1563-71.
26. Chu C, et al. Comparison of infection risks and clinical outcomes in
patients with and without SARS‐CoV‐2 lung infection under
renin–angiotensin–aldosterone system blockade: Systematic review and
meta‐analysis. Br J Clin Pharmacol. 2021;87(6):2475-92.
27. de Almeida-Pititto B, et al. Severity and mortality of COVID 19 in
patients with diabetes, hypertension and cardiovascular disease: a
meta-analysis. Diabetol Metab Syndr. 2020;12(1):1-12.
28. Di Castelnuovo A, et al. RAAS inhibitors are not associated with
mortality in COVID-19 patients: findings from an observational
multicenter study in Italy and a meta-analysis of 19 studies. Vascul
Pharmacol. 2020;135:106805.
29. Diaz-Arocutipa C, et al. Association Between ACEIs or ARBs Use and
Clinical Outcomes in COVID-19 Patients: A Systematic Review and
Meta-analysis. medRxiv. 2020.
30. Flacco ME, et al. Treatment with ACE inhibitors or ARBs and risk of
severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519-24.
31. Garg A, et al. Association of Renin Angiotensin System Blockers with
Outcomes in Patients with Covid-19: A Systematic Review and
Meta-analysis. medRxiv. 2020:2020.05.23.20111401.
32. Ghosal S, et al. The effect of angiotensin converting enzyme
inhibitors and angiotensin receptor blockers on death and severity of
disease in patients with coronavirus disease 2019 (COVID-19): A
meta-analysis. medRxiv. 2020:2020.04.23.20076661.
33. Greco A, et al. Outcomes of renin–angiotensin–aldosterone system
blockers in patients with COVID-19: a systematic review and
meta-analysis. European Heart Journal-Cardiovascular Pharmacotherapy.
2020;6(5):335-7.
34. Grover A, et al. A systematic review and meta-analysis to evaluate
the clinical outcomes in COVID-19 patients on angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers. European Heart
Journal-Cardiovascular Pharmacotherapy. 2021;7(2):148-57.
35. Guo X, et al. Decreased mortality of COVID-19 with
renin-angiotensin-aldosterone system inhibitors therapy in patients with
hypertension: a meta-analysis. Hypertension. 2020;76(2):e13-e4.
36. Hasan SS, et al. Mortality and disease severity among COVID-19
patients receiving renin-angiotensin system inhibitors: a systematic
review and meta-analysis. Am J Cardiovasc Drugs. 2020:1-20.
37. Kashour T, et al. Angiotensin Converting Enzyme Inhibitors and
Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A
Systematic Review and Meta-Analysis. Am J Ther. 2020.
38. Kerneis M, et al. Severe acute respiratory syndrome coronavirus 2
and renin-angiotensin system blockers: A review and pooled analysis.
Arch Cardiovasc Dis. 2020.
39. Koshy AN, et al. Renin–angiotensin system inhibition and risk of
infection and mortality in COVID‐19: a systematic review and
meta‐analysis. Intern Med J. 2020;50(12):1468-74.
40. Kurdi A, et al. A systematic review and meta‐analysis of the use of
renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is
the evidence so far? Pharmacology research & perspectives.
2020;8(6):e00666.
41. Lee HW, et al. Renin-angiotensin system blocker and outcomes of
COVID-19: a systematic review and meta-analysis. Thorax.
2021;76(5):479-86.
42. Lee MM, et al. Renin–angiotensin system blockers, risk of
SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and
meta-analysis. European Heart Journal—Cardiovascular Pharmacotherapy.
2020.
43. Liu X, et al. Association of angiotensin converting enzyme
inhibitors and angiotensin II receptor blockers with risk of COVID‐19,
inflammation level, severity, and death in patients with COVID‐19: a
rapid systematic review and meta‐analysis. Clin Cardiol. 2020.
44. Lo KB, et al. Angiotensin converting enzyme inhibitors and
angiotensin II receptor blockers and outcomes in patients with COVID-19:
a systematic review and meta-analysis. Expert Rev Cardiovasc Ther.
2020;18(12):919-30.
45. Megaly M, et al. Renin-angiotensin system antagonists are associated
with lower mortality in hypertensive patients with COVID-19. Scott Med
J. 2020;65(4):123-6.
46. Nunes JPL. Mortality and use of angiotensin-converting enzyme
inhibitors in COVID 19 disease: a systematic review. Porto biomedical
journal. 2020;5(6).
47. Patoulias D, et al. Renin-angiotensin system inhibitors and
COVID-19: a systematic review and meta-analysis. Evidence for
significant geographical disparities. Curr Hypertens Rep.
2020;22(11):1-13.
48. Pranata R, et al. The use of renin angiotensin system inhibitor on
mortality in patients with coronavirus disease 2019 (COVID-19): a
systematic review and meta-analysis. Diabetes & Metabolic Syndrome:
Clinical Research & Reviews. 2020;14(5):983-90.
49. Qu G, et al. Association between angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers use and the risk of
infection and clinical outcome of COVID-19: a comprehensive systematic
review and meta-analysis. medRxiv. 2020:2020.07.02.20144717.
50. Ren L, et al. Lack of association of antihypertensive drugs with the
risk and severity of COVID-19: a meta-analysis. J Cardiol.
2021;77(5):482-91.
51. Ssentongo AE, et al. Renin–angiotensin–aldosterone system
inhibitors and the risk of mortality in patients with hypertension
hospitalised for COVID-19: systematic review and meta-analysis. Open
Heart. 2020;7(2):e001353.
52. Tleyjeh IM, et al. Angiotensin Converting Enzyme Inhibitors and
Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or
Hospitalization With COVID-19 Disease: A Systematic Review and
Meta-Analysis. Am J Ther. 2022;29(1):e74-e84.
53. Usman MS, et al. A meta-analysis of the relationship between
renin-angiotensin-aldosterone system inhibitors and COVID-19. Am J
Cardiol. 2020;130:159-61.
54. Wang Y, et al. The use of renin–angiotensin–aldosterone system
(RAAS) inhibitors is associated with a lower risk of mortality in
hypertensive COVID‐19 patients: a systematic review and meta‐analysis. J
Med Virol. 2021;93(3):1370-7.
55. Xu J, et al. The effect of prior angiotensin-converting enzyme
inhibitor and angiotensin receptor blocker treatment on coronavirus
disease 2019 (COVID-19) susceptibility and outcome: a systematic review
and meta-analysis. Clin Infect Dis. 2021;72(11):e901-e13.
56. Xue Y, et al. Effects of ACEI and ARB on COVID-19 patients: A
meta-analysis. J Renin Angiotensin Aldosterone Syst.
2020;21(4):1470320320981321.
57. Yokoyama Y, et al. Association of renin‐angiotensin‐aldosterone
system inhibitors with mortality and testing positive of COVID‐19:
Meta‐analysis. J Med Virol. 2021;93(4):2084-9.
58. Zhang G, et al. Effects of renin‐angiotensin‐aldosterone system
inhibitors on disease severity and mortality in patients with COVID‐19:
A meta‐analysis. J Med Virol. 2021;93(4):2287-300.
59. Zhang Y, et al. Renin Angiotensin System Inhibition and
Susceptibility and Outcomes from COVID-19: A Systematic Review and
Meta-analysis of 69,200 COVID-19 Patients. medRxiv. 2020.
60. Pirola CJ, et al. Estimation of renin-angiotensin-aldosterone-system
(RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis. J Infect.
2020;81(2):276-81.
61. Esler M, et al. Can angiotensin receptor-blocking drugs perhaps be
harmful in the COVID-19 pandemic? J Hypertens. 2020;38(5):781-2.
62. Rico-Mesa JS, et al. Outcomes in patients with COVID-19 infection
taking ACEI/ARB. Curr Cardiol Rep. 2020;22:1-4.
63. Warner FJ, et al. Angiotensin converting enzyme-2 (ACE2) and its
possible roles in hypertension, diabetes and cardiac function. Letters
in Peptide Science. 2003;10(5):377-85.
64. Soler MJ, et al. Pharmacologic modulation of ACE2 expression. Curr
Hypertens Rep. 2008;10(5):410-4.
65. Fang L, et al. Are patients with hypertension and diabetes mellitus
at increased risk for COVID-19 infection? Lancet Respir Med.
2020;8(4):e21-e.
66. Lopes RD, et al. Effect of Discontinuing vs Continuing
Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor
Blockers on Days Alive and Out of the Hospital in Patients Admitted With
COVID-19: A Randomized Clinical Trial. Jama. 2021;325(3):254-64.
67. Snyder EM, et al. ACE2 and COVID-19: using antihypertensive
medications and pharmacogenetic considerations. Pharmacogenomics.
2020;21(10):695-703.
68. Leclercq V, et al. Psychometric measurements of AMSTAR 2 in a sample
of meta-analyses indexed in PsycINFO. Journal of Clinical Epidemiology.
2020;119:144-5.
69. Pieper D, et al. Authors should clearly report how they derived the
overall rating when applying AMSTAR 2—a cross-sectional study. Journal
of Clinical Epidemiology. 2021;129:97-103.
70. Pieper D, et al. Minor differences were found between AMSTAR 2 and
ROBIS in the assessment of systematic reviews including both randomized
and nonrandomized studies. Journal of Clinical Epidemiology.
2019;108:26-33.